Intuitive Surgical reports earnings with eyes on a 17.1% revenue increase to $2.35 billion. Last quarter, the company surpassed revenue forecasts by 3.1%, hitting $2.25 billion. Despite a mixed ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Better-than-expected news drove the market higher this week. Inflation readings, retail sales data, unemployment claims, and consumer confidence all showed an economy that continues to outperform ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as analysts view the market reaction as “overly punitive” and see an ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Labs reported a mixed bag of Q2 2025 earnings, showing impressive growth in some areas and facing headwinds in others. Sales grew by almost 7%, and adjusted EPS saw an 11% increase. Medical ...

Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...